Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Urogen Pharma (URGN)
NASDAQ:URGN
Holding URGN?
Track your performance easily
Earnings Data
Report Date
Mar 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.74Last Year’s EPS
-0.72Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2018
|% Change Since: -15.89%
|Next Earnings Date:Aug 14, 2018
Earnings Call Sentiment|Neutral
The earnings call presented a strong focus on the future potential of UGN-102 with its NDA acceptance and significant clinical progress. While JELMYTO showed notable revenue growth, the company faces challenges with gross to net erosion and increased net loss. The sentiment is balanced with a leaning towards optimism due to the strategic initiatives and strong cash position to support future growth.Company Guidance
During the UroGen Pharma Third Quarter 2024 Earnings Call, the company provided guidance on several key metrics and strategic directions. UroGen reported JELMYTO net product revenues of $25.2 million for Q3 2024, marking a 21% increase year-over-year, with expectations of low double-digit revenue growth for the full year. The company highlighted the FDA's acceptance of the NDA for UGN-102, with a PDUFA target date of June 13, 2025, and a market opportunity exceeding $5 billion in the U.S. UroGen is planning a significant expansion of its sales force to over 80 representatives to support the anticipated launch of UGN-102. Research and development expenses rose to $11.4 million, driven by the initiation of the Phase III UTOPIA trial for UGN-103, while SG&A expenses increased to $28.9 million due to pre-commercial activities for UGN-102. With $254.2 million in cash and cash equivalents, the company is well-positioned to pursue its strategic objectives and expects operating expenses for 2024 to be near the midpoint of its $175-185 million guidance range.UGN-102 NDA Acceptance
The FDA accepted the NDA for UGN-102 with a PDUFA target date of June 13, 2025. This milestone is significant for UroGen Pharma as it aims to introduce the first FDA-approved medicine for low-grade intermediate risk non-muscle invasive bladder cancer.
JELMYTO Revenue Growth
JELMYTO delivered $25.2 million in net product revenue for Q3 2024, representing a 21% year-over-year increase driven by strong patient demand and strategic focus on key accounts.
Clinical Trial Progress
Dosing in the Phase III UTOPIA trial for UGN-103 commenced, showing continued momentum in clinical development. The ENVISION trial demonstrated a 79.6% complete response rate at 3 months and 82.3% 12-month duration of response.
Strong Cash Position
UroGen ended Q3 with $254.2 million in cash and cash equivalents, providing financial stability to execute business objectives.
---
URGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
URGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $12.21 | $12.24 | +0.25% |
| Aug 13, 2024 | $14.51 | $14.96 | +3.10% |
| May 13, 2024 | $12.74 | $13.07 | +2.59% |
| Mar 14, 2024 | $17.47 | $14.33 | -17.97% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Urogen Pharma (URGN) report earnings?
Urogen Pharma (URGN) is schdueled to report earning on Mar 13, 2025, TBA Not Confirmed.
What is Urogen Pharma (URGN) earnings time?
Urogen Pharma (URGN) earnings time is at Mar 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is URGN EPS forecast?
URGN EPS forecast for the fiscal quarter 2024 (Q4) is -0.74.
---